Skip to main content

Evidence-Based Supplement Research

Evidence-Based Supplement Research

L-Carnosine and Improved Attention Span

Doses used in studies

g/day: 2 (median 2, IQR 2–2) — 1 study
mg/day: 800 (median 800, IQR 800–800) — 1 study

Time to effect

Median: 10.4 weeks · IQR 9.2 weeks–11.6 weeks · Range 8 weeks–3 months — Reported in 2 of 2 studies

Safety in these studies

Overall tolerabilityIncreased risk30% vs 14%
The carnosine group reported more adverse events (30%) compared with the placebo group (14%).
from: A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improv
Overall tolerabilityNo significant difference
The frequency of side effects was not significantly different between the two treatment arms.
from: l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyper
laboratory indicesReported
Laboratory indices remained within acceptable ranges.
from: A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improv

2 of 2 papers

l-Carnosine as Adjunctive Therapy in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
- 2018-06
- RCT
- Journal of child and adolescent psychopharmacology 28(5)
- - Alireza Ghajar
  - Farinaz Aghajan-Nashtaei
  - Mohsen Afarideh
  - Mohammad-Reza Mohammadi
  - Shahin Akhondzadeh
- PubMed: 29469593
- DOI: 10.1089/cap.2017.0157
6 Insights on
- Improved Attention Span
- High evidence
- Clinical
Improvements in the Teacher ADHD-RS were not significantly different between the two groups in total, as well as inattention and hyperactivity subscale scores (p = 0.956 and 0.281, respectively)
Effect
Neutral
Effect size
Small
Significant
No
Dose
800 mg/d in two divided doses
A preliminary, randomized, double-blind, placebo-controlled trial of L-carnosine to improve cognition in schizophrenia.
- 2012-12
- RCT
- Schizophrenia research 142(1-3)
- - K N Roy Chengappa
  - Scott R Turkin
  - Susan DeSanti
  - Christopher R Bowie
  - Jaspreet S Brar
  - Patricia J Schlicht
  - Sherry L Murphy
  - Michelle L Hetrick
  - Robert Bilder
  - David Fleet
- PubMed: 23099060
- DOI: 10.1016/j.schres.2012.10.001
11 Insights on
- Improved Attention Span
- High evidence
- Clinical
Other cognitive tests showed no significant differences between treatments
Effect
Neutral
Effect size
Small
Significant
No
Dose
2 g/day